AQR Capital Management
EIDX

AQR Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

AQR Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,249
Closed -$954K – 2319
2020
Q4 		$954K Sell
7,249
-6,274
-46% -$554K ﹤0.01% 1527
2020
Q3 		$683K Sell
13,523
-2,526
-16% -$114K ﹤0.01% 1600
2020
Q2 		$765K Sell
16,049
-3,033
-16% -$141K ﹤0.01% 1587
2020
Q1 		$935K Buy
19,082
+3,526
+23% +$180K ﹤0.01% 1364
2019
Q4 		$893K Buy
15,556
+4,217
+37% +$209K ﹤0.01% 1552
2019
Q3 		$408K Buy
+11,339
New +$443K ﹤0.01% 1819

AQR Capital Management's EIDX Position: Q1 2021 in Review

AQR Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 7,249 shares — an estimated $954K sold.

AQR Capital Management first reported a position in EIDX in Q3 2019 and held it in 6 quarters. The position peaked at $954K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • AQR Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • AQR Capital Management sold 7,249 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $954K.
  • AQR Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • AQR Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $954K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on AQR Capital Management's 13F filing for Q1 2021, filed 17 May 2021.